FDA Restricts J&J’s COVID-19 Vaccine Over Risk of Blood Clots

Jack Phillips
By Jack Phillips
May 5, 2022Health
FDA Restricts J&J’s COVID-19 Vaccine Over Risk of Blood Clots
An illustration picture shows vials with COVID-19 Vaccine stickers attached and syringes with the logo of pharmaceutical company Johnson & Johnson on Nov. 17, 2020. (Justin Tallis/AFP via Getty Images)

The U.S. Food and Drug Administration (FDA) on Thursday announced it will restrict the use of the Johnson & Johnson COVID-19 vaccine to adults who cannot receive mRNA vaccines, due to the risk of potentially life-threatening side effects.

The agency said the COVID-19 vaccine can now only be administered to people aged 18 years of age and older who can’t receive either the two-shot Moderna or Pfizer vaccines, which use mRNA technology. J&J’s single-shot vaccine uses adenovirus technology.

People who are aged 18 and older who want to receive the J&J vaccine “because they would otherwise not receive a COVID-19 vaccine” can also get it, according to the FDA’s news release. The agency did not elaborate.

Over the past several months, the FDA and other federal agencies have increasingly recommended that Americans get either the Moderna or Pfizer vaccines over the J&J shot. In December, for example, the Centers for Disease Control and Prevention (CDC) issued a recommendation that prioritized the Moderna and Pfizer vaccines over J&J’s because of safety issues.

FDA officials said in the release that they made the decision to restrict J&J’s vaccine after re-evaluating the data on the risk of life-threatening blood clots that may occur within two weeks of vaccination.

“We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in the United States and across the global community,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. “Our action reflects our updated analysis of the risk of TTS following administration of this vaccine and limits the use of the vaccine to certain individuals.” TTS refers to thrombosis with thrombocytopenia syndrome, a rare form of blood clotting.

After an analysis, the FDA found that the risk of TTS syndrome in combination with low levels of blood platelets between one and two weeks after the shot is administered warrants placing limitations on use of the vaccine, the news release said.

Marks added that officials have been “closely monitoring” the J&J vaccine and the occurrence of  TTS, while the FDA again asserted that the “known and potential benefits of the vaccine” still currently outweigh the negatives.

“The agency will continue to monitor the safety of the Janssen COVID-19 Vaccine and all other vaccines, and as has been the case throughout the pandemic, will thoroughly evaluate new safety information,” Marks added.

The agency also provided examples of people who may still receive the J&J vaccine, including people who suffered “an anaphylactic reaction after receipt of an mRNA COVID-19 vaccine,” people who have concerns about receiving mRNA vaccines and wouldn’t otherwise get a COVID-19 shot, and people who would stay unvaccinated because of limited access to mRNA COVID-19 vaccines in their areas. It’s not clear how the new guidelines will be enforced.

Johnson & Johnson has not responded to a request for comment.

COVID-19 is the illness caused by the CCP (Chinese Communist Party) virus.

From The Epoch Times

ntd newsletter icon
Sign up for NTD Daily
What you need to know, summarized in one email.
Stay informed with accurate news you can trust.
By registering for the newsletter, you agree to the Privacy Policy.